Too many cancer drugs? Crowded market gives investors pause
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil hovers near $100 on rising Middle East tensions
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Gilead Sciences (GILD) PT Lowered to $90 at RBC Capital
May 2, 2018 8:26 AM EDTRBC Capital lowered its price target on Gilead Sciences (NASDAQ: GILD) to $90.00 (from $94.00) while maintaining an Outperform rating following a disappointing quarter.
... More
Gilead Sciences (GILD) PT Lowered to $79 at Baird
May 2, 2018 7:51 AM EDTBaird lowered its price target on Gilead Sciences (NASDAQ: GILD) to $79.00 (from $87.00) while maintaining an Outperform rating on weaker than expected 1Q.
Analyst Brian Skorney commented, "While investors had projected 2018 as a trough earnings year for the company, worse than expected sales... More
Gilead Sciences (GILD) PT Lowered to $81 at Morgan Stanley
May 2, 2018 7:45 AM EDTMorgan Stanley lowered its price target on Gilead Sciences (NASDAQ: GILD) to $81.00 (from $85.00) while maintaining a Equalweight rating following the company's 1Q earnings report.
1Q18 EPS missed by $0.17. The miss was driven by lower than expected total revenues ($5.1B vs. $5.4B... More
